semaglutide approved for cardiovascular Oral to Reduce the Risk of Events FDA Approves Wegovy to Reduce

Emerging research suggests the answer may be yes

Head-to-Head Efficacy: Tirzepatide Wins 22% vs 15% Weight Loss The most robust head-to-head comparison comes from the SURPASS-2 trial, a 40-week, phase 3 study of 1,879 adults with type 2 diabetes, published in the N Engl J Med

Brazilian regulator ANVISA has received at least 4 requests to licence generic semaglutide

The two affected patients filed lawsuits against the drugmaker in New Jersey state court last week

Clinical trial data demonstrate a dose-response relationship, with higher doses generally producing greater weight loss, though the 5 mg dose is an effective maintenance dose for many patients